INSIDE INFORMATION: Bioretec updates its product pipeline to accelerate commercialization strategy following the first RemeOs™ FDA market authorization, and consequently updates financial targets
/PRNewswire/ -- Bioretec Ltd, a pioneer in bioabsorbable orthopedic implants, announced on 30 March 2023 that it had received U.S. market authorization for its...
Timo Lehtonen Bioretec Remeos Tomi Numminen Prnewswire Bioretec Ltd Finland Branch Drug Administration
Source: prnewswire.com